Background: Synthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psychoactive substances monitored by the European Union Early Warning System. Despite the wide diffusion on the market, data regarding effects, toxicities, and mechanisms as well as toxic/lethal doses are still scarce. Methods: A comprehensive literature search for articles published up to January 2019 was performed in multiple electronic databases. Only cases of death in which toxicological analyses revealed the presence of SCRAs in blood or urine and at least an external examination was performed, including those occurred in emergency departments, were included. Results: Of 380 studies identified, 354 were excluded, while 8 additional manuscri...
© 2019 The British Pharmacological Society.Novel psychoactive substances (NPS), especially those new...
Background: New psychoactive stimulants and hallucinogens comprise a range of designer drugs that ...
The aim of the study was to determine excess mortality associated with cannabis use disorders. Indiv...
Background: Synthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psy...
Background: Synthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psy...
BackgroundSynthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psych...
Synthetic cannabinoid receptor agonists (SCRAs) have been a concern to forensic toxicologists since ...
Purpose: Cumyl-PEGACLONE was the first synthetic cannabinoid (SC) with a γ-carbolinone core structur...
Aim: To identify drug-related death trends associated with synthetic cannabinoid receptor agonists (...
<p><i>Background</i>: Sixty-one autopsy cases involving cathinones and/or cannabinoids (synthetic ca...
Introduction: Use of synthetic cannabinoids (SC) has recently emerged as a new drug epidemic. Our em...
Context: Synthetic cannabinoid receptor agonists are the largest group of new psychoactive substance...
Context: MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its...
In recent years, several synthetic cannabinoid compounds have become popular recreational drugs of a...
Although the past few years have seen a significant increase in the use of synthetic cannabinoids, v...
© 2019 The British Pharmacological Society.Novel psychoactive substances (NPS), especially those new...
Background: New psychoactive stimulants and hallucinogens comprise a range of designer drugs that ...
The aim of the study was to determine excess mortality associated with cannabis use disorders. Indiv...
Background: Synthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psy...
Background: Synthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psy...
BackgroundSynthetic cannabinoid receptor agonists (SCRAs) have become the largest group of new psych...
Synthetic cannabinoid receptor agonists (SCRAs) have been a concern to forensic toxicologists since ...
Purpose: Cumyl-PEGACLONE was the first synthetic cannabinoid (SC) with a γ-carbolinone core structur...
Aim: To identify drug-related death trends associated with synthetic cannabinoid receptor agonists (...
<p><i>Background</i>: Sixty-one autopsy cases involving cathinones and/or cannabinoids (synthetic ca...
Introduction: Use of synthetic cannabinoids (SC) has recently emerged as a new drug epidemic. Our em...
Context: Synthetic cannabinoid receptor agonists are the largest group of new psychoactive substance...
Context: MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its...
In recent years, several synthetic cannabinoid compounds have become popular recreational drugs of a...
Although the past few years have seen a significant increase in the use of synthetic cannabinoids, v...
© 2019 The British Pharmacological Society.Novel psychoactive substances (NPS), especially those new...
Background: New psychoactive stimulants and hallucinogens comprise a range of designer drugs that ...
The aim of the study was to determine excess mortality associated with cannabis use disorders. Indiv...